arrow_back Trending Legislation
Share share

Increased Diversity in Clinical Trials for Drugs and Medical Devices

This act aims to boost participation of diverse demographic groups (age, sex, race, ethnicity) in clinical trials for drugs and medical devices. Companies will need to submit diversity plans and report on their progress, ensuring that medical products are safe and effective for everyone. Citizens can expect medical products to be better tailored to the needs of a diverse population.
Key points
Drug and device companies must plan and report on how they include diverse age, sex, race, and ethnic groups in their clinical trials.
If companies fail to meet diversity targets, the FDA can require additional studies after product approval to gather missing data.
The act mandates public meetings and reports on progress in increasing trial diversity and using real-world evidence.
Financial support for community health centers to participate in clinical trials and reach underrepresented communities.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
DEPICT Act
Print number: HR 6584
Sponsor: Rep. Eshoo, Anna G. [D-CA-18]
Process start date: 2022-02-03
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increased Diversity in Clinical Trials for Drugs and Medical Devices

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 6584.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-02-03.

What are the main provisions?

Key points include:

  • Drug and device companies must plan and report on how they include diverse age, sex, race, and ethnic groups in their clinical trials.
  • If companies fail to meet diversity targets, the FDA can require additional studies after product approval to gather missing data.
  • The act mandates public meetings and reports on progress in increasing trial diversity and using real-world evidence.
  • Financial support for community health centers to participate in clinical trials and reach underrepresented communities.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Eshoo, Anna G. [D-CA-18].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 6584

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health